Display options
Cite
Davis SN, Horton ES, Battelino T, et al. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010;12(4):249-55doi: 10.1089/dia.2009.0145.
Davis, S. N., Horton, E. S., Battelino, T., Rubin, R. R., Schulman, K. A., & Tamborlane, W. V. (2010). STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes technology & therapeutics, 12(4), 249-55. https://doi.org/10.1089/dia.2009.0145
Davis, Stephen N, et al. "STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects." Diabetes technology & therapeutics vol. 12,4 (2010): 249-55. doi: https://doi.org/10.1089/dia.2009.0145
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010 Apr;12(4):249-55. doi: 10.1089/dia.2009.0145. PMID: 20210562; PMCID: PMC2883476.
Copy Download .nbib Format: NLM
Share it on

Diabetes Technol Ther. 2010 Apr;12(4):249-55. doi: 10.1089/dia.2009.0145.

STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects.

Diabetes technology & therapeutics

Stephen N Davis, Edward S Horton, Tadej Battelino, Richard R Rubin, Kevin A Schulman, William V Tamborlane

Affiliations

  1. Diabetes/Endocrinology, Department of Medicine, Vanderbilt University, 2213 Garland Avenue, Nashville, TN 37232-0475, USA. [email protected]

PMID: 20210562 PMCID: PMC2883476 DOI: 10.1089/dia.2009.0145

Abstract

BACKGROUND: Sensor-augmented pump therapy (SAPT) integrates real-time continuous glucose monitoring (RT-CGM) with continuous subcutaneous insulin infusion (CSII) and offers an alternative to multiple daily injections (MDI). Previous studies provide evidence that SAPT may improve clinical outcomes among people with type 1 diabetes. Sensor-Augmented Pump Therapy for A1c Reduction (STAR) 3 is a multicenter randomized controlled trial comparing the efficacy of SAPT to that of MDI in subjects with type 1 diabetes.

METHODS: Subjects were randomized to either continue with MDI or transition to SAPT for 1 year. Subjects in the MDI cohort were allowed to transition to SAPT for 6 months after completion of the study. SAPT subjects who completed the study were also allowed to continue for 6 months. The primary end point was the difference between treatment groups in change in hemoglobin A1c (HbA1c) percentage from baseline to 1 year of treatment. Secondary end points included percentage of subjects with HbA1c < or =7% and without severe hypoglycemia, as well as area under the curve of time spent in normal glycemic ranges. Tertiary end points include percentage of subjects with HbA1c < or =7%, key safety end points, user satisfaction, and responses on standardized assessments.

RESULTS: A total of 495 subjects were enrolled, and the baseline characteristics similar between the SAPT and MDI groups. Study completion is anticipated in June 2010.

CONCLUSIONS: Results of this randomized controlled trial should help establish whether an integrated RT-CGM and CSII system benefits patients with type 1 diabetes more than MDI.

References

  1. Lancet. 2001 Feb 3;357(9253):331-5 - PubMed
  2. Acta Diabetol. 2010 Dec;47 Suppl 1:77-81 - PubMed
  3. Diabet Med. 2002 Sep;19(9):746-51 - PubMed
  4. BMJ. 2002 Oct 5;325(7367):746 - PubMed
  5. Diabetes Care. 2003 Mar;26(3):631-7 - PubMed
  6. Diabetes Care. 2003 Apr;26(4):1142-6 - PubMed
  7. Pediatrics. 2003 Sep;112(3 Pt 1):559-64 - PubMed
  8. Clin Chim Acta. 2004 Jan;339(1-2):85-90 - PubMed
  9. Diabetes Technol Ther. 2004 Apr;6(2):105-13 - PubMed
  10. Hypertension. 2004 May;43(5):924-31 - PubMed
  11. Diabetes Care. 2004 Nov;27(11):2590-6 - PubMed
  12. Biometrics. 1985 Jun;41(2):361-72 - PubMed
  13. Diabetes Care. 1987 Sep-Oct;10(5):617-21 - PubMed
  14. Mayo Clin Proc. 2004 Dec;79(12):1521-6 - PubMed
  15. Diabet Med. 2005 Jan;22(1):92-6 - PubMed
  16. Diabetes Care. 2005 Jan;28(1):15-9 - PubMed
  17. Diabetes Care. 2005 Jan;28(1):53-8 - PubMed
  18. N Engl J Med. 2008 Oct 2;359(14):1464-76 - PubMed
  19. BMJ. 2002 Mar 23;324(7339):705 - PubMed

Substances

MeSH terms

Publication Types